Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Slides:



Advertisements
Similar presentations
Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Advertisements

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation  Qing Ma, Dan Li, Roza Nurieva, Rebecca.
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Volume 33, Issue 3, Pages (September 2010)
Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease  Robert Zeiser,
Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer.
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.
Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.
Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
Volume 130, Issue 2, Pages (February 2006)
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Immune Tolerance to Self-Major Histocompatability Complex Class II Antigens after Bone Marrow Transplantation: Role of Regulatory T Cells  Allan D. Hess,
Allan D. Hess  Biology of Blood and Marrow Transplantation 
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation  Yang Wang, Dan Li, Dan Jones, Roland.
IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft- Versus-Host Disease  Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality  Kai Sun,
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses
Volume 17, Issue 12, Pages (December 2016)
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
Volume 143, Issue 1, Pages (July 2012)
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Volume 138, Issue 2, Pages (February 2010)
Volume 33, Issue 3, Pages (September 2010)
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease  Haruko Sugiyama,
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
Antigen-Presenting Cell Production of IL-10 Inhibits T-Helper 1 and 17 Cell Responses and Suppresses Colitis in Mice  Bo Liu, Susan L. Tonkonogy, R. Balfour.
Volume 27, Issue 3, Pages (September 2007)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 32, Issue 5, Pages (May 2010)
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Volume 35, Issue 2, Pages (August 2011)
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity  Jee H. Lee, Chris Elly,
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
IAPs protect host target tissues from graft-versus-host disease in mice by Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Chen Liu, Cynthia Zajac,
NK Cell Receptor NKp46 Regulates Graft-versus-Host Disease
Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease  Wonyoung Kim, Juyang.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
by Gonghua Huang, Yanyan Wang, Peter Vogel, and Hongbo Chi
Volume 37, Issue 2, Pages (August 2012)
Presentation transcript:

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing T Cells/Regulatory T Cells  Min-Jung Park, Su-Jin Moon, Sung-Hee Lee, Eun-Kyung Kim, Eun-Ji Yang, Jun-Ki Min, Sung-Hwan Park, Ho-Youn Kim, Chul-Woo Yang, Mi-La Cho  Biology of Blood and Marrow Transplantation  Volume 20, Issue 8, Pages 1112-1120 (August 2014) DOI: 10.1016/j.bbmt.2014.04.031 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 SR11302 inhibits alloreactive T cell proliferation in vitro through downregulation of AP-1/STAT3 signaling. (A) The cellular viability to SR11302 treatment in alloresponse condition in vitro was determined by MTT assay. A total of 2 × 105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 2 × 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 splenic APC (allogeneic stimulator) for 4 days. (B) In a mixed lymphocyte reaction assay, a total of 2 × 105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 2 × 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 (B6) splenic APC (allogeneic stimulator) for 4 days. Responder cells were cultured in the absence or presence of SR11302 (2.5 μM and 10 μM). SR11302 was added on day 0, and T cell proliferation was measured by [3H]-thymidine incorporation in each group. (C) The supernatants were collected, and ELISA was performed to determine the IFN-γ, IL-17, and IL-10 levels. Data represent means ± SD of triplicates (∗P < .05 versus alloresponse). (D) A total of 105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or B6 splenic APC (allogeneic stimulators). SR11302 (2.5 μM) was added on day 0 and cells were harvested on day 2. Then, western blotting analysis of AP-1 (D) and STAT3 phosphorylation associated protein expression (E) was performed in each sample. (1: syngeneic stimulator, 2: allogeneic stimulator in the absence of SR11302, 3: allogeneic stimulator in the presence of SR11302). Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Altered T cell differentiation after SR11302 treatment in donor allogeneic T cells is associated with reduced alloreactivity. (A) A total of 105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 splenic APC (allogeneic stimulator) for 4 days. Responder cells were cultured in the absence or presence of SR11302 (2.5 μM and 10 μM). SR11302 was added on day 0 and cells were harvested on day 4. Then, intracellular staining for IFN-γ, IL-17, and Foxp3 in isolated CD4+ T cells was performed and analyzed by flow cytometric analysis. Right panel shows the absolute number of CD4+IFN-γ+, CD4+IL-17+, CD4+CD25+Foxp3+ T cells. (B) Splenic T cells were incubated for 72 hours with plate-bound anti-CD3 (1 μg/mL) and anti-CD28 (1 μg/mL) antibody in the absence or presence of 10 μM SR11302. CD4+CD25+Foxp3+ Treg cell proportion was analyzed by flow cytometry. The data are expressed as the mean ± SD from 4 independent experiments. (C) The mean fluorescence intensity (MFI) of various Treg markers, including CTLA-4, ICOS, PD-1, and GITR, were analyzed by flow cytometry. The data are expressed as mean ± SD for 4 mice per group. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001, compared with the vehicle (control)-treated alloresponse. Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 SR11302 suppresses the development of acute GVHD via blocking of c-Fos/c-Jun signaling. (A) C57BL/6 (B6) splenocytes (1 × 107 cells) were incubated with 10 μM of SR11302 or DMSO (control) for 2 hours at 37°C before adoptive transfer into lethally irradiated (800 cGy) BALB/c (recipient) mice. Recipients also received 5 × 106 bone marrow cells from B6 mice and were monitored for weight loss, survival, and clinical scores of aGVHD. Lethal aGVHD shown in BALB/c recipients was inhibited after administration of donor B6 splenocytes treated with SR11302. Recipient mice receiving T cell–depleted bone marrow cells showed no signs of GVHD. Data combined from 3 independent experiments (n = 15 per group) are shown. (B) Histopathology of skin, small, and large intestine after BMT (n = 6 per group), which is representative of 2 independent experiments. Tissues isolated on day 14 after BMT were stained with H & E (original magnification, 200 ×) (left panel) and histological scores of each organ were higher in vehicle-treated animals, compared with those of SR11302–treated group (right pane). The data are expressed as the mean ± SD from 3 independent experiments for 5 mice per group. ∗P < .05, ∗∗∗P < .001, compared with the vehicle-treated GVHD group. (C) Fourteen days after BMT, splenocytes isolated from each group were stained with DAPI and anti-c-Fos or c-Jun antibodies, components of AP-1, and visualized by confocal microscopy. Representative examples of confocal staining for c-Fos and c-Jun in spleen from GVHD mice. (D) Representative examples of immunohistochemical staining for c-Fos and c-Jun, components of AP-1, in liver and small intestine tissue from GVHD mice. Positive immunoreactivity appears as a brown color and is counterstained with blue (original magnification, 400 ×). Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Analysis of CD4+ T helper cells in SR11302-treated GVHD mice. (A) C57BL/6 (B6) splenocytes (1 × 107 cells) were incubated with SR11302 (10 μM) or vehicle (DMSO) for 2 hours at 37°C before adoptive transfer into lethally irradiated (800 cGy) BALB/c mice. Recipient BALB/c mice also received 5 × 106 bone marrow cells from B6 mice. Intracellular cytokines were determined in the CD4+ T cells. Splenocytes of each group and were analyzed by flow cytometry on day 14 after BMT. Results are shown as mean ± SD (n = 5 per group). ∗P < .05, compared with the vehicle-treated GVHD group. (B) Fourteen days after BMT, the expression of Foxp3 and SOCS3 mRNA was determined by RT-PCR analysis from whole splenocytes isolated from each group. (C) Spleens isolated on day 14 after BMT in each group were analyzed by confocal microscopy for the expression of IFN-γ, IL-4, IL-17, and Foxp3 among CD4+ cells. The proportions of IFN-γ, IL-4, IL-17, or Foxp3 expressing CD4+ cells in spleen were represented by bar graph (right panel) (mean ± SD). The experiment was performed once with 6 mice per group. ∗P < .05, compared with the vehicle-treated GVHD group. Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 SR11302 regulate signaling of STAT3 and STAT5. (A) C57BL/6 (B6) splenocytes (1 × 107 cells) were incubated with SR11302 (10 μM) or vehicle (DMSO) for 2 hours at 37°C before adoptive transfer into lethally irradiated (800 cGy) BALB/c mice. Recipient BALB/c mice also received 5 × 106 bone marrow cells from B6 mice. The signal transducers STAT3 and STAT5 in the spleens were analyzed by confocal microscopy on day 14 after BMT in each group. Data are representative of 3 independent experiments. (B) Fourteen days after BMT, isolated spleens from each group were analyzed by confocal microscopy for the expression of GITR and PD-1 among CD4+CD25+Foxp3+ regulatory T cells. The experiment was performed once with 6 mice per group. Bars represent the mean ± SD of 6 mice per group. Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 SR11302 plays a critical role in Tregs-mediated inhibition of aGVHD severity. (A) Treg-depleted splenocytes (1 × 107 cells) from B6 mice were incubated with 10 μM of SR11302 or DMSO (control) for 2 hours at 37°C before adoptive transfer into lethally irradiated (800 cGy) BALB/c (recipient) mice. Recipients also received 5 × 106 bone marrow cells from B6 mice and were monitored for weight loss and survival. (B) Spleens were isolated on day 10 after BMT in each group. Then, intracellular staining for IFN-γ, IL-17, CD25, and Foxp3 in isolated CD4+ T cells was performed and analyzed by flow cytometric analysis. Biology of Blood and Marrow Transplantation 2014 20, 1112-1120DOI: (10.1016/j.bbmt.2014.04.031) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions